Webinar: State of the art ADC validation
Want to learn about antibody-drug conjugates, current and next-generation coupling technologies and the best practices to validate them ?
Please join us for our first webinar featuring :
Pr. François Romagné, Chief Scientific Officer at MI-mAbs.
Professor of immunotechnology at Aix-Marseille University (AMU) and co-founder of Innate Pharma, François Romagné contributed to the creation of MI-mAbs, where he is the Scientific Director since the start. He has accumulated extensive knowledge and experience around antibodies, both in diagnostics (14 years spent within the immunodiagnostics company Immunotech) and in therapeutic applications (14 years as Scientific Director of Innate Pharma). His expertise includes handling a large number of targets on NK cells, the TLR, and developing antibody coupling technologies. He has participated in the development of several therapeutic antibody candidates, including 2 anti-KIR and an anti-NKG2A currently in clinical development, and several others currently in pre-clinical stages (target MICA, , CD39, CD73, Siglec, …). François is the author of over 50 scientific publications and 15 patents.
Dr. Florence Lhospice, Chief Development Officer at Emergence Therapeutics.
Florence Lhospice recently joined Emergence Therapeutics as Chief Development Officer. She previously was Senior Director, Program Manager and led the ADC pre-clinical program at Innate Pharma, where she held numerous positions in the past. She was head of CMC between 2012 and 2017, after which she was in charge of the development of an ADC technology for site specific conjugation. She then led the development of ADC targets. Florence obtained a PharmD jointly from the Pharmacy School of Université Joseph Fourier Grenoble and the Université de Montréal, a Master jointly from Université Claude Bernard Lyon and the EM Lyon Business School and went on to obtain a PhD in human pathology-oncology from the Medical School of Aix-Marseille Université.
Back to events list